Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Shire
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01756157CT.gov Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks | — | Completed | — | — | — |
NCT01426763CT.gov A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Angioedema
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lispro-Ph20 Component Rhuph20 (this asset) | Shire | P2 | B · 62 |
| Firazyr | Nang Kuang Pharmaceutical Co., Ltd. | P4 | A |
| Sebetralstat | KalVista Pharmaceuticals, Ltd. | P4 | A |
| Berotralstat | BioCryst Pharmaceuticals | P3 | A |
| Lanadelumab | Takeda | P3 | A |
| Garadacimab | CSL Behring | P4 | BBB |
| Ecallantide | NYU Langone Health | P3 | BBB |
| Deucrictibant | Institute for Asthma and Allergy | P3 | BBB |
| c1 esterase inhibitor [human] | Shire | P3 | BBB |
+28 more in the Hereditary Angioedema cohort
Other indications for Lispro-Ph20 Component Rhuph20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Smoldering Plasma Cell Myeloma | — | P3 | B · 59 |
| Melanoma | — | P3 | B · 56 |
| Plasma Cell Myeloma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lispro-Ph20 Component Rhuph20 in Hereditary Angioedema. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lispro-ph20-component-rhuph20-hereditary-angioedema
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →